Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Because the rationale for MDT depends on the ablation of ... with the use of an androgen receptor pathway inhibitor, in managing castration sensitive metastatic prostate cancer,” Dr Dreicer ...

By examining genetic markers from urine or tissue samples, biomarkers provide a more precise understanding of prostate cancer’s progression and characteristics. As a urologist with over 30 years ...

Mol Cancer Ther (2025) 24 (4): 511–522. Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are ...

Objectives: The aim of this work was to review the available evidence on transperineal focal laser ablation (FLA) for patients with ... Transperineal FLA for the treatment of clinically localized ...

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors. The U.S. Food and Drug Administration (FDA) ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer ...

“A standard approach for patients with metastatic prostate cancer has been to give drugs that target the androgen receptor, and then if that fails, to give chemotherapy,” Dr. Morris explains. “But ...